Liminatus Pharma, Inc. (LIMN)
NGM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
Liminatus Pharma, Inc. has not issued a press release in this window.
SEC filings
All filings →Liminatus Pharma, Inc. has not filed an SEC document in this window.
Insider trades
All insider trades →Liminatus Pharma, Inc. has no reported insider trades in the last 90 days.
Institutional holders
All holders →No 13F holdings have been reported for Liminatus Pharma, Inc. in this window.
People at Liminatus Pharma, Inc.
All people →Quarterly financials
Full financials →No quarterly financials have been ingested for Liminatus Pharma, Inc..